Portola Pharmaceuticals (NASDAQ:PTLA) Given “Neutral” Rating at Credit Suisse Group

Credit Suisse Group reissued their neutral rating on shares of Portola Pharmaceuticals (NASDAQ:PTLA) in a research note issued to investors on Wednesday, Briefing.com Automated Import reports.

A number of other equities research analysts have also commented on PTLA. Oppenheimer set a $42.00 target price on Portola Pharmaceuticals and gave the company a buy rating in a research report on Friday, April 12th. Cowen reiterated a buy rating and issued a $149.00 target price on shares of Intercept Pharmaceuticals in a research report on Wednesday, May 8th. BidaskClub lowered ZIX from a strong-buy rating to a buy rating in a research report on Tuesday, May 21st. ValuEngine lowered Zosano Pharma from a buy rating to a hold rating in a research report on Wednesday, May 1st. Finally, William Blair restated an outperform rating on shares of Portola Pharmaceuticals in a research report on Monday, June 17th. One analyst has rated the stock with a sell rating, four have issued a hold rating and six have issued a buy rating to the company’s stock. Portola Pharmaceuticals currently has an average rating of Hold and a consensus target price of $42.29.

Shares of NASDAQ PTLA opened at $26.07 on Wednesday. The firm has a 50 day moving average price of $27.24. Portola Pharmaceuticals has a 52 week low of $14.81 and a 52 week high of $42.17. The company has a debt-to-equity ratio of 5.15, a quick ratio of 4.77 and a current ratio of 4.81.



Portola Pharmaceuticals (NASDAQ:PTLA) last issued its earnings results on Wednesday, May 8th. The biopharmaceutical company reported ($1.02) EPS for the quarter, meeting the Zacks’ consensus estimate of ($1.02). The firm had revenue of $22.17 million for the quarter, compared to analyst estimates of $20.60 million. Portola Pharmaceuticals had a negative return on equity of 238.48% and a negative net margin of 618.46%. Portola Pharmaceuticals’s revenue for the quarter was up 233.9% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($1.28) earnings per share. Sell-side analysts predict that Portola Pharmaceuticals will post -4.13 earnings per share for the current fiscal year.

In other Portola Pharmaceuticals news, Director Hollings Renton sold 5,000 shares of the company’s stock in a transaction that occurred on Monday, April 15th. The stock was sold at an average price of $34.45, for a total value of $172,250.00. Following the sale, the director now owns 14,000 shares in the company, valued at approximately $482,300. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Corporate insiders own 4.50% of the company’s stock.

Several large investors have recently made changes to their positions in the company. BlackRock Inc. lifted its position in shares of Portola Pharmaceuticals by 0.4% during the 4th quarter. BlackRock Inc. now owns 5,326,939 shares of the biopharmaceutical company’s stock valued at $103,982,000 after buying an additional 19,532 shares in the last quarter. William Blair Investment Management LLC lifted its position in shares of Portola Pharmaceuticals by 41.7% during the 1st quarter. William Blair Investment Management LLC now owns 4,154,870 shares of the biopharmaceutical company’s stock valued at $144,174,000 after buying an additional 1,222,057 shares in the last quarter. Fiera Capital Corp purchased a new position in shares of Portola Pharmaceuticals during the 1st quarter valued at approximately $53,590,000. Brandywine Global Investment Management LLC lifted its position in shares of Portola Pharmaceuticals by 11.8% during the 4th quarter. Brandywine Global Investment Management LLC now owns 834,967 shares of the biopharmaceutical company’s stock valued at $16,299,000 after buying an additional 87,999 shares in the last quarter. Finally, Geode Capital Management LLC lifted its position in shares of Portola Pharmaceuticals by 4.8% during the 4th quarter. Geode Capital Management LLC now owns 730,249 shares of the biopharmaceutical company’s stock valued at $14,254,000 after buying an additional 33,734 shares in the last quarter.

About Portola Pharmaceuticals

Portola Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes novel therapeutics in the areas of thrombosis and other hematologic disorders and inflammation in the United States. The company offers Andexxa, an antidote for patients treated with rivaroxaban and apixaban when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding; and Bevyxxa (betrixaban), an oral, once-daily Factor Xa inhibitor for the prevention of venous thromboembolism in adult patients hospitalized for an acute medical illness.

Further Reading: Gap Down Stocks

Analyst Recommendations for Portola Pharmaceuticals (NASDAQ:PTLA)

Receive News & Ratings for Portola Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Portola Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.